![](https://news.europawire.eu/wp-content/uploads/2022/01/novartis-campus-basel-e1641813163342-144x144.jpg)
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days The secondary … Read the full press release